J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea · Delayed Price · Currency is KRW 9,430.00
-780.00 (-7.64%)
At close: Sep 3, 2026
J2KBIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 43,899 | 32,966 | 33,129 | 28,472 | 16,032 | 14,219 |
Other Revenue | 0 | - | -0 | - | -0 | - |
| 43,899 | 32,966 | 33,129 | 28,472 | 16,032 | 14,219 | |
Revenue Growth | 50.99% | -0.49% | 16.36% | 77.60% | 12.75% | 2.60% |
Cost of Revenue | 26,498 | 19,987 | 20,472 | 16,970 | 8,974 | 8,289 |
Gross Profit | 17,401 | 12,979 | 12,657 | 11,502 | 7,058 | 5,929 |
Selling, General & Admin | 7,137 | 6,685 | 6,483 | 4,233 | 3,468 | 2,905 |
Research & Development | 2,708 | 2,427 | 1,902 | 1,217 | 877.86 | 778.41 |
Amortization of Goodwill & Intangibles | 72.51 | 66.3 | 55.55 | 46.94 | 41.2 | 30.79 |
Operating Expenses | 10,902 | 10,060 | 9,031 | 5,896 | 4,734 | 4,055 |
Operating Income | 6,499 | 2,920 | 3,626 | 5,607 | 2,324 | 1,874 |
Interest Expense | -42.88 | -46.63 | -95.78 | -176.48 | -258.28 | -202.13 |
Interest & Investment Income | 106.64 | 210.36 | 147.2 | 54.1 | 13.38 | 5.69 |
Currency Exchange Gain (Loss) | 30.73 | -11.29 | 11.08 | 7.4 | 15.35 | 3.21 |
Other Non Operating Income (Expenses) | -34.31 | -56.39 | -5,130 | 50.59 | 193.11 | 12.54 |
EBT Excluding Unusual Items | 6,559 | 3,016 | -1,442 | 5,542 | 2,287 | 1,693 |
Gain (Loss) on Sale of Investments | 451.87 | 44.09 | 85.7 | 36.58 | -64.4 | - |
Gain (Loss) on Sale of Assets | - | - | -4.58 | 0.11 | -39.95 | - |
Asset Writedown | -9.66 | -17.65 | - | -6.74 | - | -99.33 |
Pretax Income | 7,002 | 3,042 | -1,361 | 5,572 | 2,183 | 1,594 |
Income Tax Expense | 1,188 | 369.49 | 310.69 | 774.03 | 118.65 | -29.4 |
Earnings From Continuing Operations | 5,814 | 2,673 | -1,671 | 4,798 | 2,064 | 1,623 |
Minority Interest in Earnings | - | - | 18.77 | 45.52 | 21.85 | - |
Net Income | 5,814 | 2,673 | -1,653 | 4,844 | 2,086 | 1,623 |
Net Income to Common | 5,814 | 2,673 | -1,653 | 4,844 | 2,086 | 1,623 |
Net Income Growth | 401.75% | - | - | 132.18% | 28.53% | 10.01% |
Shares Outstanding (Basic) | 6 | 6 | 6 | 5 | 5 | 0 |
Shares Outstanding (Diluted) | 6 | 6 | 6 | 5 | 5 | 0 |
Shares Change | 1.86% | 5.39% | 9.62% | - | 8051.19% | - |
EPS (Basic) | 994.44 | 458.84 | -299.00 | 1000.99 | 448.24 | 26241.41 |
EPS (Diluted) | 994.44 | 458.84 | -299.00 | 978.27 | 414.44 | 26241.41 |
EPS Growth | 392.59% | - | - | 136.05% | -98.42% | 10.01% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 4,821 | 1,211 | 23.37 | 1,916 | 1,328 | 1,203 |
Free Cash Flow Per Share | 824.54 | 207.84 | 4.23 | 380.01 | 263.40 | 19442.01 |
Gross Margin | 39.64% | 39.37% | 38.20% | 40.40% | 44.02% | 41.70% |
Operating Margin | 14.80% | 8.86% | 10.95% | 19.69% | 14.49% | 13.18% |
Profit Margin | 13.24% | 8.11% | -4.99% | 17.01% | 13.01% | 11.42% |
Free Cash Flow Margin | 10.98% | 3.67% | 0.07% | 6.73% | 8.28% | 8.46% |
EBITDA | 8,056 | 4,420 | 4,744 | 6,241 | 2,881 | 2,380 |
EBITDA Margin | 18.35% | 13.41% | 14.32% | 21.92% | 17.97% | 16.74% |
D&A For EBITDA | 1,557 | 1,500 | 1,118 | 634.44 | 556.88 | 506.57 |
EBIT | 6,499 | 2,920 | 3,626 | 5,607 | 2,324 | 1,874 |
EBIT Margin | 14.80% | 8.86% | 10.95% | 19.69% | 14.49% | 13.18% |
Effective Tax Rate | 16.96% | 12.14% | - | 13.89% | 5.44% | - |